UTHR Q3 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$800M+6.8% YoY

Gross Profit

$699M87.4% margin

Operating Income

$389M48.6% margin

Net Income

$339M42.4% margin

EPS (Diluted)

$7.16

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

$562M

Free Cash Flow

$352M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$7.4B

Total Liabilities

$761M

Stockholders' Equity

$6.6B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$800M	$749M	+6.8%
Gross Profit	$699M	$666M	+4.9%
Operating Income	$389M	$343M	+13.2%
Net Income	$339M	$309M	+9.6%

Revenue Segments

Tyvaso

$478M60%

Orenitram

$131M16%

Remodulin

$126M16%

Unituxin

$48M6%

Adcirca

$10M1%

Product and Service, Other

$7M1%

Geographic Segments

UNITED STATES

$775M97%

Non-US

$25M3%